NeuroLicensing 2014-15 is a vital and affordable resource for licensing teams on both sides of the transaction. Completely revised and updated through July 2014, NL 2014-15 provides unique perspective on the major and midsize companies who are most involved in CNS licensing. Opportunities and partnering agendas are appraised, caution flags raised where warranted.
Current trends in deal parameters
Pharma track records in CNS licensing
What each company is looking for in terms of therapeutic areas and stages of development—and NIR’s candid evaluations of pharma performance and capabilities
Johnson and Johnson
And two to watch